We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Delta Diagnostics Stock

Invest in or calculate the value of your shares in Delta Diagnostics or other pre-IPO companies through EquityZen's platform.

Get Started

Delta Diagnostics Stock (DEDI)

Delta Diagnostics is a biotech company that creates highly sensitive and selective biosensors using integrated photonics.

About Delta Diagnostics Stock

Founded

2018

Industries

Software, Artificial Intelligence, Data and Analytics

Delta Diagnostics was founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research. It commercializes the patented biosensor technology that has been developed at the Optics department of TNO. They believe that the availability of their rapid, sensitive and low-cost biosensors and instruments will lead to new point-of-care diagnostic tests that will rely on the accurate concentration measurement of a panel of biomarkers within minutes. Since its founding, the company has grown steadily towards the highly-experienced and well-balanced team this is currently involved. During this time, it has worked hard to perfect its biosensing technology and prepare for the launch of its first product. Delta Diagnostics primarily focusses on the realization of its diagnostic test development platform and will partner with test developers to co-develop specific diagnostic tests.

Delta Diagnostics Press Mentions

Stay in the know about the latest news on Delta Diagnostics

Locked Features

Join now and verify your accreditation status to gain access to:

  • Delta Diagnostics current valuation
  • Delta Diagnostics stock price
  • Available deals in Delta Diagnostics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading Delta Diagnostics Stock

How to invest in Delta Diagnostics stock?

Accredited investors can buy pre-IPO stock in companies like Delta Diagnostics through EquityZen funds. These investments are made available by existing Delta Diagnostics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Delta Diagnostics stock?

Shareholders can sell their Delta Diagnostics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."